Kiora Pharmaceuticals Appoints New CMO, Elects Director
Ticker: KPHMW · Form: 8-K · Filed: Jul 1, 2024 · CIK: 1372514
| Field | Detail |
|---|---|
| Company | Kiora Pharmaceuticals Inc (KPHMW) |
| Form Type | 8-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.01, $120,000, $300,000, $337,000, $569,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, personnel
Related Tickers: KPRX
TL;DR
Kiora Pharma beefs up leadership with a new CMO and board member.
AI Summary
Kiora Pharmaceuticals, Inc. announced on June 28, 2024, the appointment of Dr. Michael L. Weiser as Chief Medical Officer and the election of Ms. Jennifer L. Simpson to its Board of Directors. The company also disclosed compensatory arrangements for its officers and provided updates on other events and financial statements.
Why It Matters
Changes in key leadership roles like CMO and board composition can signal strategic shifts or new directions for a pharmaceutical company's development pipeline and governance.
Risk Assessment
Risk Level: medium — Changes in executive and board positions can introduce uncertainty regarding future strategy and execution, impacting the company's risk profile.
Key Players & Entities
- Kiora Pharmaceuticals, Inc. (company) — Registrant
- Dr. Michael L. Weiser (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Simpson (person) — Elected to Board of Directors
- June 28, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer for Kiora Pharmaceuticals?
Dr. Michael L. Weiser has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors at Kiora Pharmaceuticals?
Ms. Jennifer L. Simpson has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is June 28, 2024.
What is the primary business of Kiora Pharmaceuticals, Inc. according to the filing?
Kiora Pharmaceuticals, Inc. is in the Pharmaceutical Preparations industry (SIC code 2834).
What other items are disclosed in this 8-K filing besides leadership changes?
The filing also discloses compensatory arrangements of certain officers, Regulation FD disclosures, other events, and financial statements and exhibits.
Filing Stats: 2,049 words · 8 min read · ~7 pages · Grade level 12.2 · Accepted 2024-07-01 07:00:32
Key Financial Figures
- $0.01 — nge on which registered: Common Stock, $0.01 par value KPRX NASDAQ Indicate by che
- $120,000 — the amount involved exceeds or exceeded $120,000. Appointment of Chief Financial Offic
- $300,000 — Tosca received an annual base salary of$300,000 and she was entitled to receive a perfo
- $337,000 — a's annual base salary was increased to $337,000 and her target bonus percentage was inc
- $569,000 — Officer, will receive a base salary of $569,000 and a target bonus opportunity of 55%.
- $443,000 — Officer, will receive a base salary of $443,000 and a target bonus opportunity of 40%.
- $40,000 — on for board services, as applicable: $40,000 per year for service as a board of dire
- $70,000 — hairman or lead independent director; $70,000 per year for service as non-executive c
- $15,000 — t director of the board of directors; $15,000 per year for service as chairman of the
- $8,000 — airman of the compensation committee; $8,000 per year for service as chairman of the
- $10,000 — g and corporate governance committee; $10,000 per year for service as non-chairman me
- $7,500 — airman member of the audit committee; $7,500 per year for service as non-chairman me
- $5,000 — er of the compensation committee; and $5,000 per year for service as non-chairman me
Filing Documents
- kprx-20240628.htm (8-K) — 52KB
- exhibit991.htm (EX-99.1) — 12KB
- 0001372514-24-000068.txt ( ) — 197KB
- kprx-20240628.xsd (EX-101.SCH) — 2KB
- kprx-20240628_lab.xml (EX-101.LAB) — 22KB
- kprx-20240628_pre.xml (EX-101.PRE) — 13KB
- kprx-20240628_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On July 1, 2024, the Company issued a press release announcing the appointment of Ms. Walters-Hoffert as a member of the Board, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Information contained on or accessible through any website reference in the press releases is not part of, or incorporated by reference in, this Current Report, and the inclusion of such website addresses in this Current Report by incorporation by reference of the press releases is an inactive textual references only.
01. Other Events
Item 8.01. Other Events. On June 28, 2024, the Company received notice from The Nasdaq Stock Market LLC indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Title 99.1 Press Release of Kiora Pharma ceuticals, Inc. date d July 1, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KIORA PHARMACEUTICALS, INC. By: /s/ Melissa Tosca Melissa Tosca Chief Financial Officer (Principal financial and accounting officer) Date: July 1, 2024